Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab for nummular eczema
2019-003162-41Phase 2Active
- Sponsor
- Klinikum rechts der Isar
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in discoid eczema and dermatitis comparing Dupilumab with Placebo (2 arms). Primary endpoint: Primary: Percent change in EASI score from baseline to week 16. Started Aug 2020; status: active.
02
Drugs
03
Conditions
discoid eczemadermatitis
Beyond the preview
Go deeper on 2019-003162-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003162-41.